SCHEMBL2296181

SCHEMBL2296181

CCc1nc(Cl)oc1-c1ccc(Br)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.36
TP53 P04637 4/20 0.36
LMNA P02545 3/20 0.36
CYP1A2 P05177 3/20 0.36
CYP2D6 P10635 3/20 0.36
CYP2C9 P11712 3/20 0.36
ALDH1A1 P00352 3/20 0.36
MEN1 O00255 2/20 0.36
CYP3A4 P08684 2/20 0.36
KMT2A Q03164 2/20 0.36
SLC22A1 O15245 1/20 0.36
DHFR P00374 1/20 0.36
HEXA P06865 1/20 0.36
HEXB P07686 1/20 0.36
HTR1A P08908 1/20 0.36
ADRA2A P08913 1/20 0.36
HTR2A P28223 1/20 0.36
ADRA1A P35348 1/20 0.36
HTR2B P41595 1/20 0.36
SLC6A3 Q01959 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL472477 0.80 HEXA (0.50) LMNAMEN1KMT2AHEXAHEXB
SCHEMBL472500 0.80 NOTUM (0.35) SMN1; SMN2TP53LMNACYP1A2CYP2D6
SCHEMBL472434 0.78 GBA1 (0.35) SMN1; SMN2CYP1A2NPC1RAB9AMAPK1
SCHEMBL472566 0.77 NPC1 (0.37) SMN1; SMN2LMNAALDH1A1MEN1KMT2A
SCHEMBL11747907 0.73 NR4A2 (0.50) LMNACYP1A2ALDH1A1CYP3A4KMT2A
SCHEMBL11755117 0.73 NR4A2 (0.50) LMNACYP1A2ALDH1A1CYP3A4KMT2A
SCHEMBL11754077 0.72 ALDH1A1 (0.42) SMN1; SMN2LMNACYP1A2ALDH1A1MEN1
SCHEMBL11754349 0.72 ALDH1A1 (0.42) SMN1; SMN2LMNACYP1A2ALDH1A1MEN1
SCHEMBL11748327 0.71 NPSR1 (0.46) SMN1; SMN2LMNACYP1A2CYP2C9ALDH1A1
SCHEMBL11754222 0.71 NPSR1 (0.46) SMN1; SMN2LMNACYP1A2CYP2C9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7998993-B2 TRPV1 antagonists ABBOTT LABORATORIES (US) 2011-08-16 US disclosed
EP-2220059-B1 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN ABBOTT LAB (US) 2011-08-03 EP disclosed
EP-2220059-A1 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN Abbott Laboratories (US) 2010-08-25 EP disclosed
US-20090124666-A1 TRPV1 ANTAGONISTS ABBOTT LABORATORIES (US) 2009-05-14 US disclosed
WO-2009055749-A1 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN ABBOTT LABORATORIES (US) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124666-A1 TRPV1 ANTAGONISTS TRPV1, TRPV2, TRPV3 SMN1; SMN2 2299/4885TP53 4241/4885LMNA 3611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.